Crohn's Disease
Also known as: Regional enteritis, Regional ileitis
Methodology & AI Transparency ⓘ
Crohn's Disease Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is Crohn's disease? Crohn's disease is a chronic (long-lasting) disease that causes inflammation in your digestive tract.
- 2 Real-world patient consensus: Diagnostic registry K50.90: Crohn's Disease is managed within IBS, IBD & Colon (aka Regional enteritis).
- 3 Typical cash cost range: Differential triage of Crohn's Disease (K50.90) utilizes or mucosal biologic in Crohn's Disease (K50.90: remission tracking).
- 4 Top reported side effects / signs: Objective lab/clinical target for Crohn's Disease: Fecal Calprotectin [Crohn's Disease K50.90] (< 50 mcg/g (K50.90)) and Tissue Transglutaminase IgA in Crohn's Disease (K50.90: (tTG-IgA)).
Ask our AI Specialists anything about Crohn's Disease
What Is Crohn's Disease?
What is Crohn's disease? Crohn's disease is a chronic (long-lasting) disease that causes inflammation in your digestive tract. It can affect any part of your digestive tract, which runs from your mouth to your anus. But it usually affects your small intestine and the beginning of your large intestine. Crohn's disease is an inflammatory bowel disease (IBD). Ulcerative colitis and microscopic colitis are other common types of IBD. What causes Crohn's disease? The cause of Crohn's disease is unknown. Researchers think that an autoimmune reaction may be one cause. An autoimmune reaction happens when your immune system attacks healthy cells in your body.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Crohn's Disease (ICD-10 K50.90) is driven by mucosal tight-junction permeability in Crohn's Disease (K50.90: shifts or immune-mediated); Cross-referenced with NIH MeSH (Crohn Disease), specialists in IBS, Crohn, Colitis & Bowel Disorders monitor Tissue Transglutaminase IgA in Crohn's Disease (K50.90: (tTG-IgA)) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Family history of the disease. Having a parent, child, or sibling with the disease puts you at higher risk
- • Smoking . This may double your risk of developing Crohn's disease
- • Presentation of Crohn's Disease (K50.90): alternating diarrhea, constipation, in Crohn's Disease (K50.90: urgency, or sensation)
- • Secondary Crohn's Disease clinical sign: post-meal abdominal distension, in Crohn's Disease (K50.90: gas bloating, or)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Crohn's Disease Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | K50.90 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | IBS, Crohn, Colitis & Bowel Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fecal Calprotectin [Crohn's Disease K50.90] | < 50 mcg/g (K50.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Tissue Transglutaminase IgA in Crohn's Disease (K50.90: (tTG-IgA)) | Negative (celiac rule-out) (K50.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP, CBC & in Crohn's Disease (K50.90: Ferritin) | Normal hemoglobin; hs-CRP < 1.0 mg/L (K50.90) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Crohn's Disease
Treatment selection for Crohn's Disease depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Crohn's Disease)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of Subcutaneous Vedolizumab in Patients With Moderately to: What a 275-Participant Study Found Vedolizumab SC is an effective and safe maintenance therapy in patients with CD who responded to two infusions of vedolizumab intravenous induction therapy. Journal of Crohn's & colitis • 2022-01-28 • Phase III Randomized Trial | N = 275 | 93/100 | PMID 34402887 ↗ |
| New Insights on Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the: What a 673-Participant Study Found Consistent with the primary analysis, upadacitinib was more efficacious than placebo in achieving clinical and endoscopic endpoints in. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2026-03-15 • Phase III Randomized Trial | N = 673 | 93/100 | PMID 40738276 ↗ |
| New Insights on Darvadstrocel in Patients With Crohn's Disease With Complex Perianal Fistulas:: What a 283-Participant Study Found ADMIRE CD II did not meet its primary endpoint of combined full symptom relief at week 24, with no statistically significant difference between darvadstrocel and placebo. Gastroenterology • 2026-06-15 • Phase III Randomized Trial | N = 283 | 93/100 | PMID 41790076 ↗ |
| New Insights on Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction: What a 674-Participant Study Found UPA45 provided rapid relief of clinical symptoms within the first week of treatment in patients with CD. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2024-08-15 • Phase III Randomized Trial | N = 674 | 93/100 | PMID 38492903 ↗ |
| Can This Approach Help? Inside the Latest Research on Bowel Urgency in Crohn's Disease: Effects of Mirikizumab in a Randomized Mirikizumab-treated participants achieved significantly higher rates of BU CMI and full symptom relief at weeks 12 and 52, which was associated with better short- and longer-term clinical outcomes. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2026-02-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40669578 ↗ |
Crohn's Disease Patient Community & “People Like Me” Threads
Filter Crohn's Disease community threads and patient logs by age, biological sex, dosage, and treatment duration.